Immunogenicity and protective efficacy of a recombinant lactococcus lactis vaccine against HSV-1 infection
Our study presents a novel method for constructing a recombinant vaccine using the food-grade, non-pathogenic, and non-commercial bacterium L. lactis. The findings indicate that this recombinant vaccine shows promise in preventing HSV-1 infection in mice.
Authors
- Shaoju Qian (ORCID: https://orcid.org/0000-0002-5631-1110)
- Xiangfeng Song (ORCID: https://orcid.org/0000-0002-0199-4671)
- Zhiguo Chen (ORCID: https://orcid.org/0000-0003-1508-510X)
- Aiping Sun
- Yeqing He
- Tiesuo Zhao
- Danqiong Zhang
- Zishan Yang
- Hexi Wang (ORCID: https://orcid.org/0009-0004-8794-8343)
- Lili Yu (ORCID: https://orcid.org/0000-0001-5832-1024)
- Ruixue Li (ORCID: https://orcid.org/0000-0002-2523-8416)
Institutions
- First Affiliated Hospital of Xinxiang Medical University (CN)
- Check Point (Israel) (IL)
- Henan Medical University (CN)
Publication Details
- Journal
- Microbial Cell Factories
- Published
- 2024-09-09
- DOI
- https://doi.org/10.1186/s12934-024-02517-8
- Citations
- 8
- Primary Topic
- Herpesvirus Infections and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.09
Funders
- Xinxiang Medical University